MedTrace Logo

Measurement of Risperidone and 9-Hydroxyrisperidone in Plasma and Saliva

NCT00395499 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2016-06-23

No results posted yet for this study

Summary

The purpose of this research is to: (1) examine the secrection of risperidone (RIS) (Risperdal) and its metabolite, 9-OH-RIS, in saliva, (2) determine the concentration ratio of RIS and 9-OH-RIS between plasma and saliva, and (3) compare the rate of decline in concentration of RIS and 9-OH-RIS in saliva and plasma by measurements at timed intervals during a single dosing interval.

Conditions

  • Patients Already Taking Risperidone for Clinical Indications

Interventions

DRUG

Risperidone

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Ohio State University

    lead OTHER

Principal Investigators

  • Michael G. Aman, PhD · Ohio State University

Eligibility

Min Age
4 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-05-31
Completion
2003-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00395499 on ClinicalTrials.gov